Research Article
Alleviation of Hepatic Ischemia Reperfusion Injury by Oleanolic Acid Pretreating via Reducing HMGB1 Release and Inhibiting Apoptosis and Autophagy

Wenwen Wang,1,2 Liwei Wu,2 Jingjing Li,1,2 Jie Ji,2 Kan Chen,1,2 Qiang Yu,2,3 Sainan Li,2 Jiao Feng,2 Tong Liu,2 Jie Zhang,2,3 Jiaojiao Chen,2,3 Yuting Zhou,2,3 Yuqing Mao,4 Fan Wang,5 Weiqi Dai,6 Xiaoming Fan,7 Chuanyong Guo,8,2 and Jianye Wu1

1Department of Gastroenterology, Putuo People’s Hospital, Tongji University School of Medicine, Shanghai 200060, China
2Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China
3Shanghai Tenth Hospital, School of Clinical Medicine of Nanjing Medical University, Shanghai 200072, China
4Department of Gerontology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200080, China
5Department of Oncology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200080, China
6Department of Gastroenterology, Zhongshan Hospital of Fudan University and Shanghai Institute of Liver Diseases, Zhongshan Hospital of Fudan University, Shanghai 200032, China
7Department of Gastroenterology, Jinshun Hospital of Fudan University, Jinshan, Shanghai 201508, China

Correspondence should be addressed to Chuanyong Guo; guochuanyong@hotmail.com and Jianye Wu; wjymail@163.com

Received 2 February 2019; Accepted 21 May 2019; Published 18 June 2019

Academic Editor: Daniela Caccamo

Copyright © 2019 Wenwen Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hepatic ischemia reperfusion (IR) injury (IRI) occurs during liver transplantation, hepatectomy, and hemorrhagic shock. Oleanolic acid (OA), a natural compound with antioxidant and anti-inflammatory activity that has been used to treat liver disorders in clinical practice for several years. Here, we investigated the effects and underlying mechanisms of OA in hepatic IRI. A 60-minute partial (70%) hepatic, warm, ischemic reperfusion model was established in BALB/c mice, and two doses (30 and 60 mg/kg) of OA were administered intragastrically for 7 consecutive days prior to hepatic IR. Orbital blood and liver specimens were collected at 2, 8, and 24 h after IR. The results showed that OA preconditioning significantly alleviated hepatic injury, as evidenced by decreased alanine aminotransferase and aspartate aminotransferase levels; improved histology, inhibition of JNK phosphorylation, and high mobility group box 1 (HMGB1); and tumor necrosis factor-α downregulation in hepatic IR mice. OA upregulated Bcl-2 and downregulated caspase-3, caspase-9, Bax, Beclin 1, and LC3, which play crucial roles in the regulation of apoptosis and autophagy. These findings highlighted the protective effects of OA against hepatic IRI mediated by the inhibition of apoptosis and autophagy and the release of HMGB1, which acted as a late inflammatory mediator in hepatic IRI.

1. Introduction

Hepatic ischemia-reperfusion injury (IRI) is an important cause of liver dysfunction and a serious complication of hepatic surgery and liver transplantation. Hepatic IR elicits an acute inflammatory response, leading to the formation of reactive oxygen species and the release of inflammatory cytokines, which lead to hepatocellular damage and organ failure [1, 2]. In addition to necrosis [3], other modes of cell death such as apoptosis [4, 5] and autophagy [6–8] play important roles in the mechanisms of hepatic IR.

Oleanolic acid (3β-hydroxyolean-12-en-28-oic acid, (OA)), a natural pentacyclic triterpenoid compound that is commonly found in food and in medicinal plants in the form of free acid or triterpenoid glycosides is widely distributed in plantae around the world [9, 10]. In China, OA is used as an over-the-counter oral remedy for the treatment of liver disorders such as viral hepatitis [9]. Studies show that OA
alleviates inflammation and attenuates liver injury in chemical-induced acute hepatic injury and in chronic liver fibrosis and cirrhosis in animal models, as determined by decreased liver enzymes and mitigation of hepatocellular necrosis [11–14]. OA pretreatment has protective effects on IRI of the heart and kidney during the acute phase [15–17]. The high-mobility group box 1 (HMGB1) protein is a nuclear factor and a late mediator of inflammation in sepsis [18, 19]. HMGB1 levels increase as early as 1 h after hepatic IR, and inhibition of HMGB1 activity attenuates liver tissue damage and downregulates proinflammatory cytokine expression, indicating that blocking HMGB1 may be a therapeutic target in hepatic IRI [20, 21]. In vivo and in vitro studies show that toll-like receptor 4 (TLR4) acts as a receptor for HMGB1, and the interaction between HMGB1 and TLR4 plays a key role in the mechanism of hepatic IRI [21, 22]. The aim of the present study was to examine the hepatoprotective effects of OA on hepatic IRI and explore the underlying mechanism to identify potential novel targets for the prophylaxis and treatment of liver IRI.

2. Materials and Methods

2.1. Chemicals and Reagents. OA was obtained from Sigma-Aldrich (St. Louis, MO, USA). Sodium carboxymethylcellulose (CMC-Na) was provided by Sinopharm (Shanghai, China). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) microplate test kits were obtained from Nanjing Jiancheng Bioengineering Institute (Jiancheng Biotech, China). TNF-α enzyme-linked immunosorbent assay (ELISA) kits were acquired from eBioscience (San Diego, CA, USA). The RNA polymerase chain reaction (PCR) kit was purchased from Takara Biotechnology (Dalian, China). The antibodies used in this study included mouse monoclonal antibody to β-actin (Proteintech, Chicago, IL, USA). The primary antibodies used in this study included mouse monoclonal antibody to β-actin (Proteintech, Chicago, IL, USA). The antibodies used in this study included mouse monoclonal antibody to β-actin (Proteintech, Chicago, IL, USA).

2.2. Animals. All experiments carried out on mice conformed to the National Institutes of Health Guidelines and were approved by the Animal Care and Use Committee of Shanghai Tongji University. Male Balb/c mice weighing 21–25 g (6–8 weeks old) were supplied by Shanghai SLAC Laboratory Animal Co. Ltd. (Shanghai, China). The mice were housed in plastic cages in a temperature-controlled environment of 22°C under an alternating 12 h:12 h light-dark circadian rhythm and were provided food and water ad libitum.

2.3. Experimental Design. An OA suspension was prepared with 0.5% CMC-Na aqueous solution [23]. Mice were randomly divided into five groups. Each group received an equal volume of the indicated liquid intragastrically once a day for 7 consecutive days before undergoing surgery as follows [24]:

(1) Sham group (n = 18): mice received physiological saline followed by sham operation

(2) CMC group (n = 18): mice received 0.5% CMC-Na aqueous solution followed by IR procedure

(3) IR group (n = 18): mice received physiological saline followed by IR procedure

(4) L group (n = 18): mice received 30 mg/kg OA suspension followed by IR operation

(5) H group (n = 18): mice received 60 mg/kg OA suspension followed by IR operation

2.4. Establishment of the IR Model. A well-established mouse model of segmental (70%) hepatic warm ischemia was used [25, 26]. Mice were fasted for 24 h before the operation and then anesthetized with one dose (1.25%) of sodium pentobarbital (Nembutal, St. Louis, MO, USA) intraperitoneally. Midline laparotomy was performed to expose the liver hilum. All the structures in the portal canal (hepatic artery, portal vein, and bile duct) to the left and median liver lobes were occluded with a microvascular clamp, yielding 70% hepatic ischemia. The abdomen was covered with saline-soaked gauze during the ischemic period. After 60 min, the clamp was removed to achieve reperfusion, and the abdominal incision was sewn with 4-0 silk sutures. The sham group underwent the aforementioned procedure without the vascular occlusion. An animal body temperature maintenance instrument (ZS Dihuang, Beijing, China) was used to maintain a constant body temperature during the procedure.

2.5. Sample Collection. Each group was divided into three subgroups according to sample collecting time points (2, 8, and 24 h after IR operation). At each time point, six mice per group were randomly sacrificed, and the left and median liver lobes along with orbital blood were collected.

2.6. Biochemical Analysis. After storing blood samples at 4°C for 4–5 h, serum was obtained by centrifuging at 3,000 rpm for 10 min. Serum levels of alanine transaminase (ALT) and aspartate aminotransferase (AST) were measured using an automated chemical analyzer (Olympus AU1000, Tokyo, Japan). Serum levels of TNF-α were determined with ELISA kits according to the manufacturer’s protocol.

2.7. Hepatic Histological Examination. Liver specimens removed from the left lobe were fixed in 4% paraformaldehyde and embedded in paraffin. Samples were sliced into 5 μm thick sections and stained with hematoxylin and eosin (H&E). Inflammation and tissue damage were evaluated with a light microscope. Five fields (200x magnification) per slice were examined by an experienced pathologist [27, 28]. Histo-pathological sections were evaluated according to Suzuki’s histologic grading [29]. The percentage of necrotic and edematous areas in H&E-stained liver sections was calculated using Image-Pro Plus 6.0. According to the degree of cytoplasmic vacuolization, sinusoidal congestion, and parenchymal necrosis, the liver sections were scored from 0 to 4 as previously described [28]: 0—none; 1—mild; 2—moderate; 3—marked; and 4—severe to diffuse.
2.8. **Immunohistochemistry (IHC).** Paraffin-embedded liver sections were dewaxed in xylene and dehydrated in an alcohol gradient. Antigen retrieval was achieved using citrate buffer and incubation in a 95°C water bath for 20 min. The sections were incubated with 3% hydrogen peroxide for 10 min to block endogenous peroxidases. Sections were incubated with 3% hydrogen peroxide and nonspecific antibodies and dilutions: HMGB1 (1 : 10,000), TLR4 (1 : 1,000), Beclin 1 (1 : 1,000), Bcl-2 (1 : 1,000), Bax (1 : 1,000), caspase3 (1 : 1,000), caspase9 (1 : 1,000), and β-actin (1 : 1,000). The next day, membranes were washed three times with PBS containing 0.1% Tween 20 (PBST) and then incubated with horseradish peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies at 1 : 2,000 for 1 h at room temperature. After three washes with PBST, membranes were scanned with the Odyssey two-color infrared laser imaging system, and the gray values were quantified using ImageJ v1.8.0 software.

2.11. **Statistical Analysis.** Data were presented as the mean ± standard error. Differences between groups were detected by one-way analysis of variance. A P value of <0.05 was considered statistically significant. Statistical analyses were performed with SPSS 20.0 software (Chicago, IL, USA).

### 3. Results

3.1. **OA Preconditioning Restores the Hepatic IR-Induced Increase in Serum Aminotransferase Levels.** The levels of ALT and AST were markedly higher in the IR group than in the sham group at 2, 8, and 24 h post procedure. This demonstrated the successful establishment of a segmental hepatic IR model, in which the greatest increase in aminotransferase was observed at 8 h. The elevated activities of aminotransferase at the same time points were dramatically reduced by preconditioning with 60 mg/kg OA. A 30 mg/kg dose of OA had the same effect on decreasing transaminase levels except at the 2 h time point. There was no significant difference in aminotransferase activity between the CMC group and the IR group (Figure 1(a)).

3.2. **OA Mitigates Liver Histopathological Injury Caused by Hepatic IR.** H&E staining of the liver specimens showed that hepatic lobular structures remained ordered in the sham group, whereas massive hepatic necrosis, marked neutrophil infiltration, moderate-to-severe edema, and congestion were observed in the IR and CMC groups at the three time points (Figure 1(b)). Pretreatment with OA at 30 and 60 mg/kg alleviated the histopathological changes in the IR group. No significant differences were observed between the CMC and the IR group (Figure 1(b)).
group and the IR group (Figure 1(b)). The results of pathological grading of the liver sections collected at 8 h after hepatic IR were consistent with the above results (Table 2).

### 3.3. OA Suppresses Apoptosis and Autophagy during Hepatic IR

IR induction inhibited the mRNA and protein expression of the anti-apoptotic Bcl-2 and upregulated the proapoptotic proteins caspase-3, caspase-9, and Bax. OA preconditioning upregulated Bcl-2 and downregulated Bax, caspase-9, and caspase-3 at the three time points, resulting in a decrease of the Bax/Bcl-2 ratio. Autophagy-related proteins showed a similar pattern, with high levels of expression of LC3 and Beclin 1 in the IR and CMC groups and marked downregulation of these proteins in response to OA preconditioning (Figures 2(a) and 2(b)).

### Table 2: Pathological grading for hepatic injury 8 h after IR.

<table>
<thead>
<tr>
<th></th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.50</td>
</tr>
<tr>
<td>CMC</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>4</td>
<td>3.50*</td>
</tr>
<tr>
<td>IR</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>5</td>
<td>3.83*</td>
</tr>
<tr>
<td>L</td>
<td>0</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>2.17*</td>
</tr>
<tr>
<td>H</td>
<td>0</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>1.67*</td>
</tr>
</tbody>
</table>

n = 6, *P < 0.05 versus sham, #P < 0.05 versus IR.

### 3.4. OA Inhibits HMGB1 Production and TNF-α-Mediated JNK Signaling

To explore the mechanism underlying the effects of OA, TNF-α levels were assessed by RT-PCR, ELISA,
Figure 2: OA pretreatment attenuates the intrinsic pathways of apoptosis and autophagy in hepatic IR. (a) Liver mRNA levels of Bcl-2, Bax, caspase-3, caspase-9, Beclin 1, and LC3 at 2, 8, and 24 h after hepatic IR were quantified by real-time PCR. (b) Protein expression of Bcl-2, Bax, caspase-3, caspase-9, Beclin 1, and LC3 detected by western blotting. The western blot results were quantified with ImageJ v1.8.0 software. Data are presented as mean ± standard error ($n = 6$, * $P < 0.05$ versus sham, # $P < 0.05$ versus IR).
Mediators of Inflammation

Figure 3: Continued.
and western blotting, and HMGB1 and TLR4 levels were assessed by IHC. The results showed that hepatic IR increased serum TNF-\(\alpha\) levels, which peaked at 8 h, whereas OA pretreatment significantly suppressed the increase in TNF-\(\alpha\) (Figure 3(a)). Consistent with these results, the mRNA and protein expression of TNF-\(\alpha\) were remarkably upregulated in the CMC and IR groups, whereas OA preconditioning inhibited this effect compared with hepatic IR mice (Figures 3(a), 3(c) and 3(d)). HMGB1 and TLR4 mRNA and protein levels were increased in the CMC and IR groups at the three time points, particularly at 8 and 24 h, whereas the levels were dramatically reduced by OA pretreatment. An increasing trend in JNK phosphorylation was observed in hepatic IR mice, and this effect was suppressed by pretreatment with OA suspension (Figures 3(b)–3(d)).

4. Discussion

Liver IRI is associated with clinically relevant processes such as liver transplantation, hepatectomy, and hemorrhagic shock [30]. In the past decades, several potential mechanisms were proposed to explain the occurrence of IRI. The aim of the current study was to explore the underlying mechanisms and suggest potential strategies for the prophylaxis and treatment of liver IRI.

OA is a natural product with anticancer, antimicrobial, and antidiabetic activities that is used as an alternative therapy for chronic liver diseases in China [10, 31]. In a previous study from our group, we demonstrated the protective effects of OA in a model of concanavalin A-induced acute hepatitis [28]. Whether OA plays a similar hepatoprotective role in a model of hepatic IRI and the underlying mechanisms needs further investigation. In the present study, we showed that OA has hepatoprotective effects against liver IRI biochemically and histopathologically. No significant differences in serum aminotransferase levels and pathological score were observed between the CMC and IR groups, indicating that the solvent, 0.5% CMC-Na, did not affect liver function. Previous studies showed that elevated HMGB1 is related to the pathophysiologic process of liver IR. The addition of HMGB1 promotes the release of TNF-\(\alpha\) and TNF-\(\alpha\) also facilitates the production of HMGB1 [18–21]. Liu et al. [20] and Tsung et al. [21] showed that inhibition of HMGB1 expression has hepatoprotective effects against hepatic IR, as indicated by the alleviation of histopathological injury and decreased levels of inflammatory cytokines. These findings suggest that HMGB1 is a potential target for the treatment of hepatic IRI. OA inhibits HMGB1-mediated pathway activation in lipopolysaccharide-stimulated RAW264.7 cells [32] and human umbilical vein endothelial cells [33]. HMGB1 acts as a late mediator of the inflammatory response, activating monocytes to secrete proinflammatory cytokines, including TNF-\(\alpha\) and IL-1 [34], and inducing inflammation as the ligand of TLR4 [18]. Andersson et al. provided evidence that HMGB1 increases the release of TNF in vivo and in vitro [19]. Therefore, we hypothesized that OA exerts its hepatoprotective effects by inhibiting HMGB1. The results showed that TNF-\(\alpha\) and HMGB1 were significantly upregulated at the mRNA and protein levels in hepatic IR mice at three time points, supporting the proinflammatory role
of HMGB1. OA pretreatment downregulated TNF-α and HMGB1, suggesting that OA has anti-inflammatory and HMGB1 inhibitory effects.

Apoptosis and autophagy are involved in hepatic IRI. In addition, TNF-α activates JNK signaling, and JNK phosphorylation is closely related to the induction of cellular autophagy and apoptosis [35–37]. Phosphorylation of JNK downregulates the antiapoptotic protein Bcl-2 and upregulates the proapoptotic protein Bax [38, 39], activating caspase-9 and caspase-3 signaling cascades leading to cellular apoptosis [40]. Bcl-2 interacts with the autophagy-related protein Beclin 1 through its BH3 (Bcl-2 homology 3) domain, thereby decreasing Beclin 1 activity, inhibiting autophagy, and limiting the conversion of LC3 (microtubule-associated protein 1 light chain 3) I to LC3 II [41, 42]. Jiang et al. reported an association between apoptosis and HMGB1 release, in which inhibition of JNK suppressed apoptosis resulting in decreased HMGB1 release in RAW 264.7 cells [43]. OA inhibits JNK phosphorylation, leading to the inhibition of downstream apoptosis and autophagy [28, 44]. This suggested that the protective effects of OA against hepatic IR are mediated by targeting JNK signaling activation and its effects on the regulation of hepatocellular apoptosis and autophagy. To clarify the contribution of the JNK pathway, which was downregulated in the CMC and IR groups (Figure 4).

The results of the present study provide insight into the proinflammatory role of HMGB1 in the pathophysiology of hepatic IR and suggest that OA exerts its hepatoprotective effects by decreasing HMGB1 release and inhibiting apoptosis and autophagy. These findings provide a new therapeutic option for the prophylaxis and treatment of liver IRI.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Disclosure

Liwei Wu is a co-first author.

Conflicts of Interest

The authors declare that no conflicts of interest are associated with the study.

Authors’ Contributions

Wenwen Wang, Jianye Wu, and Chuanyong Guo designed the research. Wenwen Wang, Liwei Wu, Jiao Feng, Qiang Yu, Jiaojiao Chen, Jie Ji, Jie Zhang, Yuting Zhou, Tong Liu, and Sainan Li performed the experiments and analyzed the data. Kan Chen, Yuqing Mao, Jingjing Li, Xiaoming Fan, Fan Wang, and Weiqi Dai provided new reagents or analytic tools. Wenwen Wang wrote the paper.
Acknowledgments

This work was supported by the National Natural Science Foundation of China (81670472, 81700502, and 81800538), the Shanghai Science and Technology Commission Sailing Plan (2018YF1420000), the Shanghai Putuo District Science and Technology Committee Health System Innovation Plan (ptkws201901), and the Chinese Foundation for Hepatitis Prevention and Control WBN Liver Disease Research Fund (2019031).

References


[27] B. Bhushan, C. Walesky, M. Manley et al., “Pro-regenerative signaling after acetalaminophen-induced acute liver injury in mice identified using a novel incremental dose model,” The


